Biofrontera Inc. (BFRI) vs China Pharma Holdings, Inc. (CPHI)

Biofrontera Inc. and China Pharma Holdings, Inc. are both Drug Manufacturers Specialty & Generic companies. China Pharma Holdings, Inc. is the larger, with a market value of $31.8M against $17.8M — 1.8× the size. Biofrontera Inc. grew revenue faster over the last twelve months: 17.8% against −11.0%. Biofrontera Inc. has the higher net margin (−13.8% vs −114.3%) and the lower return on invested capital (−69.5% vs −7.23%). Across the 18 metrics below, Biofrontera Inc. leads on 9 and China Pharma Holdings, Inc. on 9.

Valuation

Metric BFRI CPHI Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 0.33 7.76 2.25
P/B 2.56 0.84 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 0.34 8.52 2.56
Earnings yield (38.14%) (57.33%) (2.99%)
Free cash flow yield (52.00%) (1.10%) 0.00%

Profitability

Metric BFRI CPHI Drug Manufacturers Specialty & Generic median
Gross margin 79.25% 11.76% 53.94%
Operating margin (14.22%) (111.84%) 0.00%
Net margin (13.78%) (114.33%) 0.00%
Free cash flow margin (17.17%) (3.59%) 0.00%
Return on equity (988.35%) (20.99%) (0.40%)
Return on assets (28.80%) (15.30%) (3.32%)
Return on invested capital (69.45%) (7.23%) 0.00%

Growth

Metric BFRI CPHI Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 17.83% (10.97%) 10.01%
EPS growth (last fiscal year) 67.70% 72.59% —
Revenue growth, 5-year CAGR 17.21% (17.53%) 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BFRI CPHI Drug Manufacturers Specialty & Generic median
Debt to equity 0.78 0.05 0.05
Current ratio 1.18 0.26 2.31
Net debt to EBITDA 0.17 (0.98) 0.85

Dividend

Metric BFRI CPHI Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric BFRI CPHI Drug Manufacturers Specialty & Generic median
Market cap 17.82m 31.83m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack